TILD + matching placebo injections
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active Psoriatic Arthritis
Conditions
Active Psoriatic Arthritis
Trial Timeline
Jul 1, 2020 → Apr 1, 2026
NCT ID
NCT04314531About TILD + matching placebo injections
TILD + matching placebo injections is a phase 3 stage product being developed by Sun Pharmaceutical for Active Psoriatic Arthritis. The current trial status is active. This product is registered under clinical trial identifier NCT04314531. Target conditions include Active Psoriatic Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Active Psoriatic Arthritis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04314544 | Phase 3 | Completed |
| NCT04314531 | Phase 3 | Active |
Competing Products
20 competing products in Active Psoriatic Arthritis